Results 1 to 10 of about 505,796 (149)
Best practices for engaging with affected communities: chronic hepatitis B as a case study [PDF]
Hepatitis B is the single most common cause of liver cancer, affecting > 250 million people worldwide (mostly in resource limited communities) and killing > 1 million people annually. The condition is marked by poor rates of diagnosis (14%) and treatment
Thomas Tu+20 more
doaj +2 more sources
Background In 2019, an estimated 296 million people were living with chronic hepatitis B virus (HBV) globally with approximately 2.4 million living within the United States.
Catherine Freeland+6 more
doaj +1 more source
Background An estimated between 257 and 292 million people live with chronic HBV globally. While much is known about the causes, and epidemiology of HBV, little is understood about the quality of life and impact of HBV on those living with the infection.
Catherine Freeland+8 more
doaj +1 more source
The International Liver Association recommends the use of accurate and sensitive molecular methods for determination of hepatitis B virus (HBV) DNA levels in plasma or serum of chronic HBsAg carriers. The level of HBV replication represents the strongest
Valérie Ortonne+7 more
doaj +1 more source
Background An estimated 296 million individuals live with chronic hepatitis B worldwide, most have not been diagnosed and remain at risk of liver disease and cancer.
Catherine Freeland+4 more
doaj +1 more source
Chronic hepatitis B virus (HBV) infection is a global health threat. Mutations in the surface antigen of HBV (HBsAg) may alter its antigenicity, infectivity, and transmissibility.
Felix Lehmann+9 more
doaj +1 more source
Background Located in southwestern Indian Ocean, Mayotte is a French territory, with a very specific demographic, social and health context. To date, epidemiological data on infections by hepatitis B (HBV), C (HCV), and delta (HDV) viruses in Mayotte ...
Cécile Brouard+10 more
doaj +1 more source
Chronic hepatitis B infection (HBV) disproportionately affects African Immigrant (AI) communities in the U.S., with a reported infection rate of 15%. HBV screening rates within these communities are low.
Catherine Freeland+3 more
doaj +1 more source
Nasvac (HeberNasvac®) is a novel therapeutic vaccine for chronic hepatitis B (CHB). This product is a formulation of the core (HBcAg) and surface (HBsAg) antigens of the hepatitis B virus (HBV), administered by nasal and subcutaneous routes, in a ...
Julio Cesar Aguilar+2 more
doaj +1 more source
Perceptions and patient care needs among hepatitis B patients during COVID-19
Background The novel coronavirus of 2019 (COVID-19) has been and continues to be a rapidly developing public health crisis, that has also disrupted routine and maintenance health care for people living with chronic conditions.
Sherrie Flynt Wallington+5 more
doaj +1 more source